161 related articles for article (PubMed ID: 9927037)
21. [Mutation analysis of the tumor suppressor gene PTEN/MMAC1/TEP1 in human hepatocellular carcinoma].
Zhang LN; Zha XL; Yu Q; He JY
Shi Yan Sheng Wu Xue Bao; 2000 Sep; 33(3):223-7. PubMed ID: 12549040
[TBL] [Abstract][Full Text] [Related]
22. Down-regulation of transforming growth factor beta receptor type III in hepatocellular carcinoma is not directly associated with genetic alterations or loss of heterozygosity.
Bae HJ; Eun JW; Noh JH; Kim JK; Jung KH; Xie HJ; Park WS; Lee JY; Nam SW
Oncol Rep; 2009 Sep; 22(3):475-80. PubMed ID: 19639191
[TBL] [Abstract][Full Text] [Related]
23. Caspase-8 gene is frequently inactivated by the frameshift somatic mutation 1225_1226delTG in hepatocellular carcinomas.
Soung YH; Lee JW; Kim SY; Sung YJ; Park WS; Nam SW; Kim SH; Lee JY; Yoo NJ; Lee SH
Oncogene; 2005 Jan; 24(1):141-7. PubMed ID: 15531912
[TBL] [Abstract][Full Text] [Related]
24. Molecular cytogenetic evaluation of virus-associated and non-viral hepatocellular carcinoma: analysis of 26 carcinomas and 12 concurrent dysplasias.
Zondervan PE; Wink J; Alers JC; IJzermans JN; Schalm SW; de Man RA; van Dekken H
J Pathol; 2000 Oct; 192(2):207-15. PubMed ID: 11004697
[TBL] [Abstract][Full Text] [Related]
25. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas.
Taniguchi K; Roberts LR; Aderca IN; Dong X; Qian C; Murphy LM; Nagorney DM; Burgart LJ; Roche PC; Smith DI; Ross JA; Liu W
Oncogene; 2002 Jul; 21(31):4863-71. PubMed ID: 12101426
[TBL] [Abstract][Full Text] [Related]
26. Tumor-suppressor effect of interferon regulatory factor-1 in human hepatocellular carcinoma.
Moriyama Y; Nishiguchi S; Tamori A; Koh N; Yano Y; Kubo S; Hirohashi K; Otani S
Clin Cancer Res; 2001 May; 7(5):1293-8. PubMed ID: 11350897
[TBL] [Abstract][Full Text] [Related]
27. [Epitope of somatic mutations in the hepatocyte growth factor receptor naturally processed and presented by HLA-A2 on human hepatocellular carcinoma].
Guo A; Sui Y; Ye J
Zhonghua Yi Xue Za Zhi; 2001 Jan; 81(1):30-2. PubMed ID: 11798848
[TBL] [Abstract][Full Text] [Related]
28. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.
Ma PC; Kijima T; Maulik G; Fox EA; Sattler M; Griffin JD; Johnson BE; Salgia R
Cancer Res; 2003 Oct; 63(19):6272-81. PubMed ID: 14559814
[TBL] [Abstract][Full Text] [Related]
29. [p16 and cyclinD1 protein expression and p16 gene mutation in primary human hepatocellular carcinoma].
Huang GX; Cheng RX; Feng DY
Hunan Yi Ke Da Xue Xue Bao; 2001 Dec; 26(6):527-30. PubMed ID: 12536530
[TBL] [Abstract][Full Text] [Related]
30. Reduced p21(WAF1/CIP1) protein expression is predominantly related to altered p53 in hepatocellular carcinomas.
Shi YZ; Hui AM; Takayama T; Li X; Cui X; Makuuchi M
Br J Cancer; 2000 Jul; 83(1):50-5. PubMed ID: 10883667
[TBL] [Abstract][Full Text] [Related]
31. The clinical value of hepatocyte growth factor and its receptor--c-met for liver cancer patients with hepatectomy.
Wu F; Wu L; Zheng S; Ding W; Teng L; Wang Z; Ma Z; Zhao W
Dig Liver Dis; 2006 Jul; 38(7):490-7. PubMed ID: 16627020
[TBL] [Abstract][Full Text] [Related]
32. [Study on p53 gene mutation in hepatocellular carcinoma patients in China].
Kang G; Fang Z; Volkmann M
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2001 Jun; 15(2):163-5. PubMed ID: 11436649
[TBL] [Abstract][Full Text] [Related]
33. Microsatellite instability and p53 mutations in hepatocellular carcinoma.
Karachristos A; Liloglou T; Field JK; Deligiorgi E; Kouskouni E; Spandidos DA
Mol Cell Biol Res Commun; 1999; 2(3):155-61. PubMed ID: 10662591
[TBL] [Abstract][Full Text] [Related]
34. Epidermal growth factor receptor expression and gene copy number in fibrolamellar hepatocellular carcinoma.
Buckley AF; Burgart LJ; Kakar S
Hum Pathol; 2006 Apr; 37(4):410-4. PubMed ID: 16564914
[TBL] [Abstract][Full Text] [Related]
35. Novel mutations of the MET proto-oncogene in papillary renal carcinomas.
Schmidt L; Junker K; Nakaigawa N; Kinjerski T; Weirich G; Miller M; Lubensky I; Neumann HP; Brauch H; Decker J; Vocke C; Brown JA; Jenkins R; Richard S; Bergerheim U; Gerrard B; Dean M; Linehan WM; Zbar B
Oncogene; 1999 Apr; 18(14):2343-50. PubMed ID: 10327054
[TBL] [Abstract][Full Text] [Related]
36. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1.
Satoh S; Daigo Y; Furukawa Y; Kato T; Miwa N; Nishiwaki T; Kawasoe T; Ishiguro H; Fujita M; Tokino T; Sasaki Y; Imaoka S; Murata M; Shimano T; Yamaoka Y; Nakamura Y
Nat Genet; 2000 Mar; 24(3):245-50. PubMed ID: 10700176
[TBL] [Abstract][Full Text] [Related]
37. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas.
Di Renzo MF; Olivero M; Martone T; Maffe A; Maggiora P; Stefani AD; Valente G; Giordano S; Cortesina G; Comoglio PM
Oncogene; 2000 Mar; 19(12):1547-55. PubMed ID: 10734314
[TBL] [Abstract][Full Text] [Related]
38. [Universal presence of HBVx gene and its close association with hotspot mutation of p53 gene in hepatocellular carcinoma of prevalent area in China].
Zhang F; Zhu Y; Sun Z
Zhonghua Zhong Liu Za Zhi; 1998 Jan; 20(1):18-21. PubMed ID: 10921048
[TBL] [Abstract][Full Text] [Related]
39. [Comparative genomic classification of human hepatocellular carcinoma].
Kaposi-Novák P
Magy Onkol; 2009 Mar; 53(1):61-7. PubMed ID: 19318328
[TBL] [Abstract][Full Text] [Related]
40. MET receptor is overexpressed but not mutated in oral squamous cell carcinomas.
Morello S; Olivero M; Aimetti M; Bernardi M; Berrone S; Di Renzo MF; Giordano S
J Cell Physiol; 2001 Dec; 189(3):285-90. PubMed ID: 11748586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
